PolyPid (NASDAQ:PYPD) vs. Insulet (NASDAQ:PODD) Head-To-Head Review

Insulet (NASDAQ:PODD) and PolyPid (NASDAQ:PYPD) are both medical companies, but which is the better stock? We will compare the two businesses based on the strength of their institutional ownership, risk, valuation, earnings, analyst recommendations, profitability and dividends.

Valuation and Earnings

This table compares Insulet and PolyPid’s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insulet	$1.87 billion	8.03	$206.30 million	$3.30	65.08
PolyPid	N/A	N/A	-$23.86 million	($12.64)	-0.27

Insulet has higher revenue and earnings than PolyPid. PolyPid is trading at a lower price-to-earnings ratio than Insulet, indicating that it is currently the more affordable of the two stocks.

Institutional & Insider Ownership

26.5% of PolyPid shares are owned by institutional investors. 0.5% of Insulet shares are owned by company insiders. Comparatively, 24.7% of PolyPid shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Analyst Ratings

This is a summary of current ratings and target prices for Insulet and PolyPid, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insulet	0	3	12	0	2.80
PolyPid	0	0	1	0	3.00

Insulet currently has a consensus price target of $225.29, indicating a potential upside of 4.91%. PolyPid has a consensus price target of $14.00, indicating a potential upside of 306.98%. Given PolyPid’s stronger consensus rating and higher probable upside, analysts clearly believe PolyPid is more favorable than Insulet.

Risk and Volatility

Insulet has a beta of 1.21, suggesting that its share price is 21% more volatile than the S&P 500. Comparatively, PolyPid has a beta of 1.31, suggesting that its share price is 31% more volatile than the S&P 500.

Profitability

This table compares Insulet and PolyPid’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Insulet	21.11%	30.73%	9.10%
PolyPid	N/A	-969.85%	-121.65%

Summary

Insulet beats PolyPid on 8 of the 13 factors compared between the two stocks.

About Insulet

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours. The company sells its products primarily through independent distributors and pharmacy channels, as well as directly in the United States, Canada, Europe, the Middle East, Australia, and internationally. Insulet Corporation was incorporated in 2000 and is headquartered in Acton, Massachusetts.

About PolyPid

PolyPid Ltd., a clinical-stage biopharmaceutical company, developing targeted, locally administered, and prolonged-release therapeutics using its proprietary polymer-lipid encapsulation matrix (PLEX) technology to address unmet medical needs. Its lead product candidate is D-PLEX100, which is in a pivotal Phase 3 confirmatory trial for prevention of surgical site infections (SSIs) in patients undergoing abdominal colorectal surgery with large incisions. It is also developing OncoPLEX, for the treatment of intra-tumoral cancer. PolyPid Ltd. was incorporated in 2008 and is headquartered in Petah Tikva, Israel.